TissueGen solves for unmet needs through the development of transformative drug delivery technologies that reduce treatment burden and improve clinical outcomes. We create life changing treatment modalities for patients and their caregivers, treating both acute and chronic conditions.
TissueGen was founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at The University of Texas Southwestern Medical Center at Dallas, and The University of Texas at Arlington. TissueGen’s initial technology was developed by our founder, Dr. Kevin Nelson. Dr. Nelson set out to solve the difficult problem of loading sensitive biological therapeutics into extruded biodegradable fibers in a way that would preserve both the biological activity of the therapeutic and the mechanical integrity of the fiber. More than 20 years later, we have never lost our fascination and drive to protect biological therapeutics from the frequently harsh conditions required to make biodegradable fibers, microspheres, as well as other delivery systems.
We focus on preserving the biological activity of very sensitive therapeutics such as growth factors and antibodies when they are loaded into polymeric systems for slow, sustained release. We started by using a simple emulsion to create a two-phase system that could be extruded into strong, biologically active fiber. As we developed, we realized this simple emulsion system could be dramatically improved by incorporating various forms of nanotechnology. We have continued to improve this technology, reaching greater than 90% preserved activity post-fiber extrusion for several antibodies and growth factors. The two-phase drug delivery system has remained a philosophical pillar and has now borne unprecedented results for long-term delivery of these sensitive therapeutics.